Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Russell, Beth; Moss, Charlotte; George, Gincy; Santaolalla, Aida; Cope, Andrew; Papa, Sophie; Hemelrijck, Mieke Van

doi:10.3332/ecancer.2020.1022

Cited by 400 publications

(421 citation statements)

References 80 publications

Supporting

Mentioning

402

Contrasting

Unclassified

Order By: Relevance

“…In conclusion, the existing literature does not currently provide conclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients, though there appears to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection [14]. However, it is important to note this is not specific to COVID-19.…”

Section: Resultsmentioning

confidence: 92%

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Russell¹,

Moss²,

Rigg³

et al. 2020

ecancer

Self Cite

263

270

View full text Add to dashboard Cite

Given the current SARS-CoV-2 (COVID-19) pandemic, the availability of reliable information for clinicians and patients is paramount. There have been a number of reports stating that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids may exacerbate symptoms in COVID-19 patients. Therefore, this review aimed to collate information available in published articles to identify any evidence behind these claims with the aim of advising clinicians on how best to treat patients. This review found no published evidence for or against the use of NSAIDs in COVID-19 patients. Meanwhile, there appeared to be some evidence that corticosteroids may be beneficial if utilised in the early acute phase of infection, however, conflicting evidence from the World Health Organisation surrounding corticosteroid use in certain viral infections means this evidence is not conclusive. Given the current availability of literature, caution should be exercised until further evidence emerges surrounding the use of NSAIDs and corticosteroids in COVID-19 patients.

show abstract

Section: Resultsmentioning

confidence: 92%

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Russell¹,

Moss²,

Rigg³

et al. 2020

ecancer

Self Cite

263

270

View full text Add to dashboard Cite

show abstract

“…63 However, there remains no evidence that NSAIDs worsen disease outcomes in COVID-19 patients. 61,62,64,65 Further, some studies have actually suggested a benefit to NSAID use. 62,66 A 2006 study demonstrated that indomethacin may actually have antiviral activity against the SARS-CoV.…”

Section: Postpartum Nsaid Use For Puis or Covid-19-positive Patientsmentioning

confidence: 99%

General Guidelines in the Management of an Obstetrical Patient on the Labor and Delivery Unit during the COVID-19 Pandemic

et al. 2020

View full text Add to dashboard Cite

Novel coronavirus disease 2019 (COVID-19) is a respiratory tract infection that was first identified in China. Since its emergence in December 2019, the virus has rapidly spread, transcending geographic barriers. The World Health Organization and the Centers for Disease Control and Prevention have declared COVID-19 as a public health crisis. Data regarding COVID-19 in pregnancy is limited, consisting of case reports and small cohort studies. However, obstetric patients are not immune from the current COVID-19 pandemic, and obstetric care will inevitably be impacted by the current epidemic. As such, clinical protocols and practice on labor and delivery units must adapt to optimize the safety of patients and health care workers and to better conserve health care resources. In this commentary, we provide suggestions to meet these goals without impacting maternal or neonatal outcomes. Key Points • Novel coronavirus disease 2019 (COVID-19) is a pandemic.• COVID-19 impacts care of obstetric patients.• Health care should be adapted for the COVID-19 pandemic.

show abstract

“…On the other hand, it has been postulated that immune system over-activation is responsible for the lung injury caused by SARS-CoV-2 and that a subgroup of patients might actually benefit from immunosuppressive drugs. 3 Similar to a recent publication concerning atopic dermatitis, 4 a panel of AIBD experts from different academic centres addressed questions regarding COVID-19 and the use of common immunomodulators (corticosteroids, azathioprine, mycophenolate mofetil/sodium, cyclophosphamide, methotrexate, cyclosporine, dapsone/sulphapyridine, doxycycline/tetracycline, colchicine, rituximab, high-dose intravenous immunoglobulins [IVIG] and immunoadsorption/plasmapheresis) in patients with AIBDs.…”

Section: Editormentioning

confidence: 99%

“…Of note, there is some evidence that prednis(ol)one may potentially have beneficial impacts on COVID-19. 3 Can we predict interactions of AIBDs, its complications and immunomodulating therapies with COVID-19?…”

Section: Editormentioning

confidence: 99%

Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic

Kasperkiewicz

Schmidt

Fairley

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Cited by 400 publications

References 80 publications

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

General Guidelines in the Management of an Obstetrical Patient on the Labor and Delivery Unit during the COVID-19 Pandemic

Expert recommendations for the management of autoimmune bullous diseases during the COVID‐19 pandemic

Contact Info

Product

Resources

About